324518

eIF4E/eIF4G Interaction Inhibitor II, 4E1RCat

The eIF4E/eIF4G Interaction Inhibitor II, 4E1RCat controls the biological activity of eIF4E/eIF4G interaction. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

• 別名: eIF4E/eIF4G Interaction Inhibitor II, 4E1RCat, 4-((3 E)-3-((5-(4-Nitrophenyl)furan-2-yl)methylidene)-2-oxo-5-phenyl-2,3-dihydro-1H-pyrrol-1-yl)benzoic acid, eIF4F Inhibitor II
• 実験式（ヒル表記法）: C₂₈H₁₈N₂O₆
• 分子量: 478.45
• UNSPSCコード: 12352200
• NACRES: NA.32

特性

• 品質水準: 100
• アッセイ: ≥97% (HPLC)
• 形状: solid
• メーカー／製品名: Calbiochem^®
• 保管条件: OK to freeze; protect from light
• 色: dark brown
• 溶解性: DMSO: 50 mg/mL
• 輸送温度: ambient
• 保管温度: 2-8°C

詳細

詳細

A cell-permeable oxopyrrolyl benzoate compound that blocks the assembly of eukaryotic translation initiation factor (eIF) 4F complex (eIF4F) as well as disrupts preformed eIF4F by competing against eIF4G for eIF4E binding. Specifically blocks cap-dependent, but not cap-independent, protein translations in cell-free translation assays and inhibits protein, but not DNA or RNA, synthesis in MDA-MB-231 and HeLa cultures (50 µM) in a reversible manner. Although not effective when administered alone (15 mg/kg, i.p. daily for 5 days), 4E1RCat is shown to significantly prolong Pten^+/-Eµ-myc and Tsc^+/-Eµ-myc, but not Eµ-myc, tumor remission time when combined with Doxorubicin (Cat. No. 324380) treatment (10 mg/kg, i.p. once on day 2) in mice in vivo. Unlike 4EGI-1 (Cat. No. 324517), 4E1RCat also blocks eIF4E and 4E-BP1 interaction.

A cell-permeable oxopyrrolyl benzoate compound that blocks the assembly of eukaryotic translation initiation factor (eIF) 4F complex (eIF4F) as well as disrupts preformed eIF4F by competing against eIF4G for eIF4E binding. Specifically blocks cap-dependent, but not cap-independent, protein translations in cell-free translation assays and inhibits protein, but not DNA or RNA, synthesis in MDA-MB-231 and HeLa cultures (50 µM) in a reversible manner. Although not effective when administered alone (15 mg/kg, i.p. daily for 5 days), 4E1RCat is shown to significantly prolong Pten^+/-Eµ-myc and Tsc^+/-Eµ-myc, but not Eµ-myc, tumor remission time when combined with Doxorubicin (Cat. No. 324380) treatment (10 mg/kg, i.p. once on day 2) in mice in vivo. Unlike 4EGI-1 (Cat. No. 324517), 4E1RCat also blocks eIF4E and 4E-BP1 interaction.

包装

Packaged under inert gas

警告

Toxicity: Standard Handling (A)

再構成

Very fluffy material, not recommended for subdividing solid material by hand-weighing. Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

その他情報

Cencic, R., et al. 2011. Proc. Natl. Acad. Sci. USA108, 1046.

法的情報

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

安全性情報

• 保管分類コード: 11 - Combustible Solids
• WGK: WGK 3
• 引火点(°F): Not applicable
• 引火点(℃): Not applicable